Cargando…

ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES

Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb),...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Kai, Li, Huishuai, Tang, Chuanlong, Zhang, Dawei, Zhang, Xuejian, Zhang, Ying, Zhao, Zhengyang, Zhou, Jun, Lu, Mengjie, Xiao, Yongsheng, Feng, Zhumei, Wu, Jiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370427/
http://dx.doi.org/10.1093/abt/tbad014.017
_version_ 1785077931601559552
author Jiang, Kai
Li, Huishuai
Tang, Chuanlong
Zhang, Dawei
Zhang, Xuejian
Zhang, Ying
Zhao, Zhengyang
Zhou, Jun
Lu, Mengjie
Xiao, Yongsheng
Feng, Zhumei
Wu, Jiansheng
author_facet Jiang, Kai
Li, Huishuai
Tang, Chuanlong
Zhang, Dawei
Zhang, Xuejian
Zhang, Ying
Zhao, Zhengyang
Zhou, Jun
Lu, Mengjie
Xiao, Yongsheng
Feng, Zhumei
Wu, Jiansheng
author_sort Jiang, Kai
collection PubMed
description Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb), bispecific antibodies (bsAbs) as well as other Fc fusion proteins. High-throughput production (HTP) of various proteins with high quality in very short time is a big challenge in industry. Here we present how WuXi Biologics has created a powerful ultra HTP protein production platform (termed as “Ultra 96”) that can automatically produce proteins within 3 weeks with one step purification at 1~3mL expression scale by using 96 and 24 well DWP. High titer of expression, high quality of products, short timeline as well as low cost make “Ultra 96” a robust platform which can empower our clients and dramatically accelerate their early stage drug discovery projects.
format Online
Article
Text
id pubmed-10370427
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-103704272023-07-27 ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES Jiang, Kai Li, Huishuai Tang, Chuanlong Zhang, Dawei Zhang, Xuejian Zhang, Ying Zhao, Zhengyang Zhou, Jun Lu, Mengjie Xiao, Yongsheng Feng, Zhumei Wu, Jiansheng Antib Ther Abstract Proteins are known as the building blocks of life which play many critical roles in the body. In early stage drug discovery, numerous μg to mg scale high quality proteins need to be produced for in vitro functional studies and therapeutic evaluation, including antigens, monoclonal antibodies (mAb), bispecific antibodies (bsAbs) as well as other Fc fusion proteins. High-throughput production (HTP) of various proteins with high quality in very short time is a big challenge in industry. Here we present how WuXi Biologics has created a powerful ultra HTP protein production platform (termed as “Ultra 96”) that can automatically produce proteins within 3 weeks with one step purification at 1~3mL expression scale by using 96 and 24 well DWP. High titer of expression, high quality of products, short timeline as well as low cost make “Ultra 96” a robust platform which can empower our clients and dramatically accelerate their early stage drug discovery projects. Oxford University Press 2023-07-24 /pmc/articles/PMC10370427/ http://dx.doi.org/10.1093/abt/tbad014.017 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For Permissions, please email: journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstract
Jiang, Kai
Li, Huishuai
Tang, Chuanlong
Zhang, Dawei
Zhang, Xuejian
Zhang, Ying
Zhao, Zhengyang
Zhou, Jun
Lu, Mengjie
Xiao, Yongsheng
Feng, Zhumei
Wu, Jiansheng
ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title_full ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title_fullStr ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title_full_unstemmed ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title_short ESTABLISHMENT OF AN ULTRA HIGH-THROUGHPUT PROTEIN PRODUCTION PLATFORM (ULTRA 96) FOR EARLY STAGE IN VITRO STUDIES
title_sort establishment of an ultra high-throughput protein production platform (ultra 96) for early stage in vitro studies
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10370427/
http://dx.doi.org/10.1093/abt/tbad014.017
work_keys_str_mv AT jiangkai establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT lihuishuai establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT tangchuanlong establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT zhangdawei establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT zhangxuejian establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT zhangying establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT zhaozhengyang establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT zhoujun establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT lumengjie establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT xiaoyongsheng establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT fengzhumei establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies
AT wujiansheng establishmentofanultrahighthroughputproteinproductionplatformultra96forearlystageinvitrostudies